Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
Bella Mehta bella_mehta
1 week 1 day ago
Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026
Presence on leucocytes- change from pro inflammatory to anti inflammatory casade
Also in fibroblasts in rheumatoid arthritis.
Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey
1 week 1 day ago
#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio
sheila RHEUMarampa
1 week 1 day ago
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
Bella Mehta bella_mehta
1 week 1 day ago
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow
Summary below. https://t.co/QC0Li38eh6
Mrinalini Dey DrMiniDey
1 week 1 day ago
After failure of a first TNFi in axSpA, #OP0235 from ROC-SpA trial found no superiority of switching to an IL-17A inhibitor over cycling to second TNFi. ASAS40 responses at Week 24 similar with both strategies, supporting individualised treatment decisions. #EULAR2026 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 POS0729 Longer-term data of autologous CD19 CAR-T appear favourable in #SLE. 4-year data of the initial 8 patients treated at Erlangen remained in GC- and IS-free remission. Infection profile declined over time apart from some blips during COVID pandemic @RheumNow https://t.co/QZMxA2CK33
Mrinalini Dey DrMiniDey
1 week 1 day ago
Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP022 We need to think beyond proteinuria to assess activity & response in #lupusnephritis. ReBioLup study showed 67% of patients with persistent histologic activity at 12 months (NIH=>4) still met criteria for complete clinical response @RheumNow https://t.co/bRFNrNLjJX
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti
Janet Pope Janetbirdope
1 week 1 day ago
What to use in #RA #IL6i v #abatacept post #TNFi-IR?
H2H #TCZ v #Abatacept
Same on primary outcome
#CDAI change wk26
BUT
If #monoRx TCZ better
Better retention #TCZ
So you decide which is better! Equal v some advantages w #tocilizumab
#EULAR2026 @RheumNow @eular_org
#OP0205 https://t.co/xdOx4kQCTC
Aurelie Najm AurelieRheumo
1 week 1 day ago
Leflunomide is not associated w/ incident or progressive ILD
Longitudinal CT Study 184 RA pts
LEF exposure inversely asso w/ new lung involvement
#POS062 #EULAR2026 @RheumNow https://t.co/LBrfycalLf
Janet Pope Janetbirdope
1 week 1 day ago
Brand new #MOA in #Rx of #skin #lupus!
#Litifilimab - acts on #dendritic cells
⬇️decreases
#chemokines & #cytokines
+RCT in #cutaneous features of lupus
N=93
2:1 randomized #liti v #pbo
Rapid onset <4wks
HIgh #CLASI response
#EULARbest #EULAR226 @RheumNow @eular_org POS438 https://t.co/TXqggO1jCU
Aurelie Najm AurelieRheumo
1 week 1 day ago
SCOOT study oral split-dose vs SC MTX RA
Primary outcome EULAR mod/good response wk16
Non-inferiority NOT met
EULAR good response lower with oral split-dose OR 0.53
ACR50 lower with oral split-dose OR 0.51
Safety oral split-dose Higher transaminitis (>2× ULN)
3 serious AEs https://t.co/c8etFKtGwo
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 1 day ago
#EULAR2026 OP Are we closer to controlled trials of CAR-T? Miv-cel KYV-101 autologous CD19 CAR-T reported efficacy and safety profile in 6 patients with severe refractory #RA (median prior bDMARDs: 6) in Phase I COMPARE. Will proceed to Phase II with RTX as a comparator @RheumNow https://t.co/Rb4BFgBDZE
